TABLE 7.

Comparison of the in vitro activities of the various antimicrobial agents against clinical isolates of Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus

Organism (na) and antimicrobial agents	MIC (μg/ml)				%Sb
	Range	Mode	50%	90%
Prevotella spp. (65)
Piperacillin-tazobactam	≤0.06–8	≤0.06	≤0.06	≤0.06	100
Ampicillin-sulbactam	≤0.03–8	0.5	1	4	100
Penicillin G	≤0.015–>32	8	4	16	17
Cefoxitin	≤0.015–16	1	1	4	100
Imipenem	≤0.015–0.12	0.03	0.03	0.06	100
Meropenem	≤0.015–0.5	0.03	0.03	0.12	100
Ciprofloxacin	≤0.015–>32	8	8	16	35
Trovafloxacin	≤0.008–4	1	1	1	97
Clindamycin	≤0.008–>16	0.015	0.015	4	89.2
Metronidazole	≤0.12–4	2	2	2	100
Fusobacterium spp. (22)
Piperacillin-tazobactam	≤0.06–1	≤0.06	≤0.06	0.12	100
Ampicillin-sulbactam	≤0.03–4	≤0.03	≤0.03	0.25	100
Penicillin G	≤0.015–8	≤0.015	≤0.015	0.5	91
Cefoxitin	≤0.015–16	≤0.015	0.03	0.5	100
Imipenem	≤0.015–0.25	≤0.015	≤0.015	0.03	100
Meropenem	≤0.015–0.25	≤0.015	≤0.015	0.12	100
Ciprofloxacin	≤0.015–16	≤0.015	0.5	2	96
Trovafloxacin	≤0.008–4	≤0.008	0.12	0.5	96
Clindamycin	≤0.008–>16	≤0.008	0.015	0.12	91
Metronidazole	≤0.12–8	≤0.12	≤0.12	2	100
Porphyromonas spp. (19)
Piperacillin-tazobactam	≤0.06–8	≤0.06	≤0.06	1	100
Ampicillin-sulbactam	≤0.03–2	0.03	0.12	1	100
Penicillin G	≤0.015–16	≤0.015	0.03	4	79
Cefoxitin	≤0.015–>32	≤0.015	0.25	4	95
Imipenem	≤0.015–1	≤0.015	0.03	0.06	100
Meropenem	≤0.015–1	≤0.015	0.03	0.25	100
Ciprofloxacin	≤0.015–4	1	1	4	90
Trovafloxacin	≤0.015–1	1	0.5	1	100
Clindamycin	≤0.008–8	0.015	0.015	8	90
Metronidazole	≤0.12–2	2	2	2	100
Peptostreptococcus (49)
Piperacillin-tazobactam	≤0.06–8	≤0.06	≤0.06	0.25	100
Ampicillin-sulbactam	≤0.03–16	≤0.03	0.12	0.5	96
Penicillin G	≤0.015–8	≤0.015	0.06	0.5	94
Cefoxitin	≤0.015–16	≤0.015	0.06	2	100
Imipenem	≤0.015–1	≤0.015	≤0.015	0.06	100
Meropenem	≤0.015–2	≤0.015	≤0.015	0.25	100
Ciprofloxacin	≤0.015–16	2	1	8	86
Trovafloxacin	≤0.008–8	0.5	0.25	2	94
Clindamycin	≤0.008–>16	0.25	0.12	2	92
Metronidazole	≤0.12–>64	≤0.12	0.5	2	94

^an, number of isolates tested. 

^bPercent susceptible isolates.